Caladrius Biosciences, Inc. (LSTA) Reports Q4 Loss of $0.76/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Caladrius Biosciences, Inc. (LSTA) Reports Q4 Loss of $0.76/sh

Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 30, 2023 4:05 PM EDT

BASKING RIDGE, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (Lisata or the Company), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provides a business update and reports financial results for the three and twelve months ended December 31, 2022.

Last year (2022) was a year of major transformation, excitement and renewed energy for Lisata, allowing us to enter 2023 with growing momentum as we continue to build an enduring pharmaceutical company, stated David J. Mazzo, Ph.D., Chief Executive Officer of... More